Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan.
Department of Anesthesiology, Mackay Memorial Hospital, Hsinchu, Taiwan.
Pain. 2019 Jan;160(1):210-223. doi: 10.1097/j.pain.0000000000001395.
Nerve injury-induced neuropathic pain is difficult to treat. In this study, we used exosomes derived from human umbilical cord mesenchymal stem cell (UCMSC) as a cell-free therapy for nerve injury-induced pain in rats. Isolated UCMSC exosomes range in size from 30 to 160 nm and contain CD63, HSP60, and CD81 exosome markers. After L5/6 spinal nerve ligation surgery, single intrathecal injection of exosomes reversed nerve ligation-induced mechanical and thermal hypersensitivities of right hindpaw of rats at initial and well-developed pain stages. Moreover, continuous intrathecal infusion of exosomes achieved excellent preventive and reversal effects for nerve ligation-induced pain. In immunofluorescent study, lots of Exo-green-labelled exosomes could be found majorly in the ipsilateral L5 spinal dorsal horn, dorsal root ganglion, and peripheral axons, suggesting the homing ability of UCMSC exosomes. They also appeared in the central terminals or cell bodies of IB4, CGRP, and NF200 sensory neurons. In addition, exosome treatment suppressed nerve ligation-induced upregulation of c-Fos, CNPase, GFAP, and Iba1. All these data suggest that the analgesic effects of exosomes may involve their actions on neuron and glial cells. Exosomes also inhibited the level of TNF-α and IL-1β, while enhanced the level of IL-10, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor in the ipsilateral L5/6 dorsal root ganglion of nerve-ligated rats, indicating anti-inflammatory and proneurotrophic abilities. Protein analysis revealed the content of vascular endothelial growth factor C, angiopoietin-2, and fibroblast growth factor-2 in the exosomes. In summary, intrathecal infusion of exosomes from UCMSCs may be considered as a novel therapeutic approach for nerve injury-induced pain.
神经损伤诱导的神经性疼痛难以治疗。在这项研究中,我们使用源自人脐带间充质干细胞(UCMSC)的外泌体作为一种无细胞治疗方法,用于治疗大鼠神经损伤引起的疼痛。分离的 UCMSC 外泌体的大小在 30 至 160nm 之间,包含 CD63、HSP60 和 CD81 外泌体标志物。在 L5/6 脊神经结扎手术后,单次鞘内注射外泌体可逆转大鼠右后爪在初始和完全发展的疼痛阶段的神经结扎引起的机械和热敏性过敏。此外,连续鞘内输注外泌体可实现对神经结扎引起的疼痛的出色预防和逆转作用。在免疫荧光研究中,大量 Exo-green 标记的外泌体主要在同侧 L5 脊髓背角、背根神经节和外周轴突中发现,表明 UCMSC 外泌体的归巢能力。它们也出现在 IB4、CGRP 和 NF200 感觉神经元的中央末端或细胞体中。此外,外泌体治疗抑制了神经结扎引起的 c-Fos、CNPase、GFAP 和 Iba1 的上调。所有这些数据表明,外泌体的镇痛作用可能涉及它们对神经元和神经胶质细胞的作用。外泌体还抑制了 TNF-α 和 IL-1β 的水平,同时提高了神经结扎大鼠同侧 L5/6 背根神经节中 IL-10、脑源性神经营养因子和胶质细胞源性神经营养因子的水平,表明具有抗炎和神经营养作用。蛋白质分析显示外泌体中血管内皮生长因子 C、血管生成素-2 和成纤维细胞生长因子-2 的含量。总之,鞘内输注 UCMSC 的外泌体可能被认为是一种治疗神经损伤引起的疼痛的新方法。